The platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs, says MilliporeSigma, which is the US and Canada life science business of Merck KGaA of Germany.
“Cell and gene therapies offer the potential for curative treatments and can be commercialized in half the time compared to traditional therapies,” said Dirk Lange, Head of Life Science Services, Life Science business sector of Merck KGaA, Darmstadt, Germany.
“By increasing dose yields and dramatically reducing process development time, our VirusExpress 293 AAV Production Platform will accelerate manufacturing of these therapies, ultimately delivering lifesaving treatments to patients faster.”
Headquartered in Burlington, Massachusetts, MilliporeSigma is a CDMO and has been involved in this space since clinical trials for gene therapy began in the 1990s. In October 2021, the company opened its second Carlsbad, California-based facility, more than doubling its existing production capacity to support large-scale commercial manufacturing.
Commenting on the VirusExpress 293 AAV Production Platform launch, it says: “The new platform is an extension of the company’s VirusExpress offering, which can reduce process development time by up to 40%.
“The company’s VirusExpress Lentiviral Production Platform has enabled customers to increase the speed to clinical manufacturing, achieve five times higher titer than the leading competitor, and transition a legacy process to a templated solution.